Recently, Xu et al. from Deng’s lab have introduced and characterized the first-in-class small molecule KRAS agonist that activates both the wild-type and mutant KRAS molecules and has shown selective effects towards KRAS mutant lung cancer in-vitro and in-vivo57. This evidence concerns the gene KRAS and lung carcinoma.